Table 2 Specific CDK7 inhibitors in breast cancer clinical trials
From: CDK7 in breast cancer: mechanisms of action and therapeutic potential
Name | NCT Number | Clinical Phase | Status | Conditions | Administration route | Interventions |
|---|---|---|---|---|---|---|
SY5609 | NCT04247126 | Phase 1 | Completed | Advanced or metastatic HR+/HER2- breast cancer who failed prior treatment with a CDK4/6 inhibitor in combination with hormonal therapy in a previous line of therapy | Orally | Drug:SY5609 Drug: Fulvestrant |
Q901 | NCT05394103 | Phase 1/2 | Recruiting | Advanced or metastatic HR+/HER2- breast cancer, who have progressed following standard-of-care therapy | Intravenous infusion | Drug: Q901 |
CT7001 | NCT03363893 | Phase 1/2 | Completed | Locally advanced or metastatic TNBC, HR+ /HER2- breast cancer | Orally | Drug: CT7001 Drug: CT7001 in combination with fulvestrant |
SY1365 | NCT03134638 | Phase 1 | Terminated | Advanced or metastatic HR+/HER2- breast cancer who failed prior treatment with a CDK4/6 inhibitor in combination with hormonal therapy in a previous line of therapy | Intravenous infusion | Drug:SY1365 Drug: Fulvestrant |
XL102 | NCT04726332 | Phase 1 | Recruiting | Advanced or metastatic HR+/HER2- breast cancer, TNBC, who have progressed following standard-of-care therapy | Orally | Drug: XL102 Drug: Fulvestrant |
TY-2699a | NCT05866692 | Phase 1 | Recruiting | Locally advanced or metastatic TNBC, HR+/HER2- breast cancer | Orally | Drug: TY-2699a |
GTAEXS-617 | NCT05985655 | Phase 1/2 | Recruiting | Advanced breast carcinoma (HR+/HER2- that has progressed to a prior treatment with CDK4/6 inhibitor) | Orally | Drug: GTAEXS-617 |